Imprimis Pharmaceuticals Launches Imprimis Cares Access Network (ICAN) to Assist in Patient Access to Imprimis Cares Compounded Formulations

Source: Imprimis Pharmaceuticals

Imprimis Pharmaceuticals announced the launch of the Imprimis Cares Access Network (ICAN), a new patient assistance program designed to simplify the process of accessing Imprimis' patent-pending Tiopronin Delayed Release (Tiopronin-DR) compounded formulations, a lower cost alternative to Thiola, as well as other Imprimis Cares compounded formulations, according to a company news release.

Sam S., a 45-year old male Imprimis Cares patient from Alabama, stated, "I have been taking Thiola for nearly 20 years and was relieved when I learned Imprimis Pharmaceuticals had introduced a lower-cost tiopronin alternative. The new Tiopronin-DR formulation is significantly more affordable for my employer, which is self-insured, and allows me to reduce the number of pills I take from 15 pills per day to 6. I fully support the Imprimis Cares program and its mission of providing all Americans access to affordable prescription drugs. I am now enrolled in automatic refills to ensure my medication is delivered to my home each month. It has been a pleasure working with the Imprimis team and patient advocates during my changeover from Thiola to Tiopronin-DR and I cannot thank them enough for the time they devoted on my behalf to ensure access to this formulation now covered by my insurance."

Tiopronin is commonly prescribed for the treatment of cystine stone formation in the kidneys, ureter, and bladder in cystinuria patients who do not respond to dietary changes and increased fluids. Imprimis' tiopronin compounded formulations may not only significantly lower the cost of cystinuria treatments but also allow patients, for the first time, to reduce the number of pills they consume on a daily basis for this chronic genetic disease. Imprimis' exclusive National Drug Code (NDC) for tiopronin should allow patients and their insurance companies to experience a reduction in costs of more than 70% compared to the FDA-approved Thiola per 100mg dose. 

The ICAN team of dedicated patient advocates will work with physicians, their office staff, insurance carriers, and pharmacy benefit managers (PBMs) to facilitate and expedite the insurance payment process on behalf of patients enrolled in the program. The network also provides assistance and support for eligible patients to substantially decrease or eliminate out-of-pocket expenses. Enrollees have the option to receive emails and brochures with updates and other helpful information about their condition and treatment options.

To learn more or to enroll, please visit https://www.imprimisrx.com/why-imprimisrx/imprimis-cares/ican/.  

"The new ICAN program is powered by the good relationships we have been able to build with leading PBMs and their plan sponsors who, like Imprimis, are 100% committed to making sure patients have access to affordable critical medicines prescribed by a physician," Mark L. Baum, Chief Executive Officer of Imprimis, said in the news release. "The ICAN team, working in concert with our payor partners, help support cystinuria patients and their families as they transition from higher cost medicines to the Imprimis Cares formulary. We would like to thank our payor partners for working with us to develop the ICAN program which ensures affordable access to critical medicines. In the future, we intend to continue to expand the Imprimis Cares formulary to drive value for patients, payors and our shareholders."

Tiopronin Delayed Release Formulations

Physicians and their cystinuria patients may now choose from one of two lower-cost compounded alternatives to Thiola.

  • Tiopronin Delayed Release is comprised of the active ingredient tiopronin along with a cellulose-based FDA-approved delayed release agent. This formulation is available in various customizable doses including 200mg and 250mg capsules.
  • Tiopronin-K Delayed Release is comprised of the active ingredient tiopronin along with potassium citrate in a delayed release capsule, for those patients who have had their potassium citrate dosing titrated. Potassium citrate is the first-line alkalinizing drug for the treatment of cystinuria.  According to the National Organization for Rare Disorders, in addition to chelating medications such as tiopronin, potassium citrate is often co-prescribed and taken separately to make the urine more alkaline, potentially reducing cystine crystallization and stone formation.

Related Content